Bernard A. Fox

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
February, 2025
February 2025
M T W T F S S
 12
3456789
10111213141516
17181920212223
2425262728  

Bernard A. Fox
Feb 14, 2025, 02:46 | Blog
Bernard A. Fox: Three goals I have followed for the last 31 years
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, reshared a post by OncoDaily on…
Feb 13, 2025, 17:58 | Blog
Bernard A. Fox: We need to do more for every patient fighting cancer
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared on LinkedIn: "A friend of mine…
Jan 27, 2025, 09:24 | Blog
Bernard A. Fox: UbiVac is excited to have the world’s 1st immunotherapy that targets cancer’s Dark Matter
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared on LinkedIn: "Ryan Witt thanks…
Dec 29, 2024, 11:07 | Science
The highest cited original research publications in Pancreatic Cancer from 2020 to 2024 by Anirban Maitra
Anirban Maitra, Professor of Pathology and Translational Molecular Pathology at UT MD Anderson Cancer Center,…
Dec 8, 2024, 13:05 | Blog
Bernard A. Fox: Fighting for better funding for lung cancer research
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared a post by Stand Up To…
Nov 25, 2024, 13:13 | Insight
Thomas Duhen: IL-12 drives the expression of NKG2A on human tumor-reactive CD8 T cells
Thomas Duhen, Assistant Member at Earle A. Chiles Research Institute, shared an article on LinkedIn:…
Nov 20, 2024, 18:33 | Blog
Bernard A. Fox: R. Bryan Bell has accepted the roles of executive medical director of Providence Cancer Institute
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, reshared a post by Providence Cancer…
Nov 18, 2024, 10:06 | Blog
Bernard A. Fox: Speaking at Nyulangone Medical Center at the celebration of the life and legacy of Jeffrey S. Weber
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared a post on LinkedIn: "It…
Nov 17, 2024, 07:58 | Blog
523 Gene test identifies 67% of patients for Targeted Therapy or Immunotherapy
Bernard A. Fox, Adjunct Professor in the Department of Molecular Microbiology and Immunology at the…
Nov 11, 2024, 11:50 | Societies
Highlights from the 39th Society for Immunotherapy of Cancer Annual Meeting
The 39th Society for Immunotherapy of Cancer (SITC) Annual Meeting was held from November 6–10, 2024,…
Oct 30, 2024, 19:35 | Blog
Bernard A. Fox: Omid Hamid on best treatment options for patients with melanoma and other solid cancers
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared a post on LinkedIn: "Always…
Oct 29, 2024, 12:27 | Blog
Bernard A. Fox: THINK TANK VIII - A vision of what Immuno-oncology is and challenges us to consider what it can be
Bernard A. Fox, Co-Founder, President, and CEO of UbiVac, shared a post on LinkedIn: "THINK…
Sep 2, 2024, 17:43 | Blog
Bernard A. Fox: First time for me to participate in this type of satellite program, but it won’t be my last!
Bernard A. Fox, Co-Founder and CEO of UbiVac shared on LinkedIn: “What a great evening…
Jul 1, 2024, 17:27 | Blog
Bernard A. Fox: A new generation of immunotherapy clinical trials
Bernard A. Fox, Co-Founder and CEO of UbiVac shared on LinkedIn: “Great to be in…
May 1, 2024, 11:59 | Opinion
Bernard A. Fox: Dark Matter is the biggest breakthrough in cancer immunotherapy of the last 3 years
Bernard A. Fox, Co-Founder and CEO of UbiVac shared on LinkedIn: “Best response rate for recurrent…
Apr 25, 2024, 14:48 | Blog
Bernard A. Fox: Guidelines for Optimizing NBTXR3 Nanoparticle Injection in Head and Neck Cancer: A Collaborative Achievement
Bernard A. Fox, Co-Founder and CEO of UbiVac, shared on LinkedIn: "Wonderful to start the week…
Dec 21, 2023, 16:37 | Blog
Bernard A. Fox: Dr. Steven A. Rosenberg had an almost magical power
Bernard A. Fox, Co-Founder and CEO of UbiVac, shared on LinkedIn: "It is a walk down…
All: 17 Posts: 1 - 100
Special Coverage